DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity – Part 2
What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?
DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity – Part 1
Why hasn’t DMSO been dethroned—and what’s finally threatening its reign?
Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes – Part 2
For decades, contract development and manufacturing organizations (CDMOs) have grown by building bigger stainless-steel facilities and squeezing ever-tighter margins.
Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes – Part 1
What if continuous microbial manufacturing wasn’t a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?
High-Throughput Microbial Screening: Avoiding Early Mistakes That Derail Scale-Up – Part 2
For many biotech innovators, high throughput screening platforms promise faster discoveries and streamlined workflows.
High-Throughput Microbial Screening: Avoiding Early Mistakes That Derail Scale-Up – Part 1
Why do so many promising biotech ideas stall—long before they reach the clinic or marketplace?
Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months – Part 2
Imagine medicines grown like crops, ready for harvest in days, not months.
Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months – Part 1
But what if you could grow life-saving antibodies in a greenhouse instead?
Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered – Part 2
Complex automation often arrives wrapped in hype, but the reality is more nuanced.
Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered – Part 1
Are you struggling with automation projects that spiral into unnecessary complexity or fail to solve the real problem in bioprocessing?